Methoxyluteolin

Key Product Details

Product Description

Methoxyluteolin inhibits release of pro-inflammatory mediators from mast cells and decreases gene expression and release of TNF, VEGF and IL-8/CXCL8. The product also significantly inhibits IL-33 stimulated expression and release of CCL5 and CCL2. Methoxyluteolin pretreatment of LAD2 mast cells decreases gene expression of TNF, CXCL8 and VEGF in response to neurotensin or substance P via mTOR activation.

Product Specifications for Methoxyluteolin

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Methoxyluteolin

The following data is based on the product molecular weight 342.35.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	14.60 mL	73.02 mL	146.05 mL
1 mM	2.92 mL	14.60 mL	29.21 mL
2 mM	1.46 mL	7.30 mL	14.60 mL
10 mM	0.29 mL	1.46 mL	2.92 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Taracanova Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin. Proc.Nat.Acad.Sci. USA 2018 PMID: 30232261
• Weng The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J.Allergy Clin.Immunol. 2015 PMID: 25498791
• Patel and Theoharides Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. J.Pharmacol.Exp.Ther. 2017 PMID: 28404689
• Abubakr Bawazeer and Theoharides IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-κB, inhibited by methoxyluteolin. Eur.J.Pharmacol. 2019 PMID: 31669588

Product Documents for Methoxyluteolin